Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: Correlation with tumor burden

Clinical Cancer Research

Volumn 2, Issue 8, 1996, Pages 1405-1409

  Mouawad, Roger ^a   Benhammouda, Ahmed ^a   Rixe, Olivier ^a   Antoine, Eric Charles ^a   Borel, Christian ^a   Weil, Marise ^a   Khayat, David ^a   Soubrane, Claude ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; GROWTH INHIBITION; HUMAN; IMMUNE RESPONSE; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; MALE; MELANOMA; MIDDLE AGED;

EID: 0029782311     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Guerry, D., and Schuchter, L. M. Disseminated melanoma - is there a new standard therapy? N. Engl. J. Med., 327: 560-561, 1992.
2. Rosenberg, S. A. Immunotherapy of cancer using interleukin-2. Current status and future prospects. Immunol. Today, 9: 58-62, 1988.
3. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Linehan, W., Seipp, C., Calabro, S., Karp, S., Sherry, R., Steinberg, S., and White, D. E. Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol., 7: 1863-1874, 1989.
4. Atzpodien, J., Korfer, A., Franks, C., Poliwoda, H., and Kirchener, H. Home therapy with recombinant IL-2 and recombinant Interferon α 2b in advanced human malignancies. Lancet, 335: 1509-1512, 1990.
5. Sosman, J. A., Kohler, P. C., Hank, J. A., Moore, K. H., Bechhofer, R., Storer, B., and Sondel, P. M. Repetitive weekly cycles of interleukin-2 (IL-2): II. Clinical and immunologic effects of dose, schedule and indomethacin. J. Natl. Cancer Inst., 80: 1451-1461, 1988.
6. Khayat, D., Borel, C., Tourani, J. M., Benhammouda, A., Antoine, E., Rixe, O., Vuillemin, E., Bazex, P. A., Thill, L., Franks, R., Auclerc, G., Soubrane, Cl., Banzet, P., and Weil, M. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon α-2a for metastatic melanoma. J. Clin. Oncol., 11. 2173-2180, 1993.
7. Rosenberg, S. A., Grimm, E. A., McGrogan, M., Doyle, M., Kawasaki, E., Koths, K., and Mark, D. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science (Washington DC), 223: 1412-1417, 1984.
8. Weidmann, E., Bergmann, L., Stock, J., Kirsten, R., and Mitrou, P S. Rapid cytokine release in cancer patients treated with interleukin-2. J Immunother., 12: 123-131, 1992.
9. Kishimoto, T. The biology of interleukin-6. Blood, 74: 1-10, 1989.
10. Hirano, T., Akira, S , Taga, T., and Kishimoto, T. Biological and clinical aspects of interleukin-6. Immunol. Today, 11: 443-449, 1990.
11. Le, J., and Vilcek, J. Interleukin-6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab. Invest., 61: 588-602, 1989.
12. Eustace, D., Han, X., Gooding, R., Rowbottom, A., Riches, P., and Heyderman, E. Interleukm-6 functions as an autocrine growth factor in cervical carcinomas in vitro. Gynecol Oncol., 50 15-19, 1993.
13. Miki, S., Iwano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T., and Kishimoto, T. Interleukin-6 functions as an in vitro autocrine growth factor in renal cell carcinoma. FEBS Lett., 250: 607-610, 1989.
14. Lahm, H., Petral-Malec, D., Yilmaz-Ceyhan, A., Fischer, J. R., Lorenzoni, M., Givel, J. V., and Odartchenko, N. Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor β1. Eur. J. Cancer., 28A: 1894-1899, 1992.
15. Chen, L., Mory, Y., Zilberstain, A., and Revel, M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-β2. Proc. Natl. Acad. Sci. USA, 85: 8037-8041, 1989.
16. Tam, I., Cardinale, I , Krueger, J., Murphy, J. S., May, L. T., and Sehgal, P. B. Interleukin-6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J. Exp. Med., 170: 1649-1669, 1989.
17. Zhang, X. G., Klein, B., and Bataille, R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood, 74: 11-13, 1989.
18. Blay, J. V., Negrier, S., Combaret, V., Attali, S., Goillot, E , Merrouche, Y., Mercatello, A , Revault, A., Tourani, J. M , Moskovtchenko, J. F., Philip, T., and Favrot, M. Serum level of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res., 52: 3317-3322, 1992.
19. Kurzrock, R., Redman, J., Cabanillas, F., Jones, D., Rothberg, J., and Talpaz, M. Serum IL-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res., 53: 2118-2122, 1993.
20. Soubrane, C., Mouawad, R., Ichen, M., Suissa, J., Borel, C., Vuillemin, E., Benhammouda, A., Bizzari, J. P., Weil, M., and Khayat, D. Follow-up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. Clin. Exp. Immunol., 95: 232-237, 1994.
21. Mouawad, R., Ichen, M., Rixe, O., Khayat, D., Vuillemin, E., Benhammouda, A., Weil, M., and Soubrane, C. Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma Clin. Exp. Immunol., 97: 342-346, 1994.
22. Ludwig, H., Nachabaur, D. M., Fritz, E., Krainer, M., and Huber, H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood, 77: 2794-2798, 1991.
23. Bataille, R., Jourdan, M., Zang, X. G., and Klein, B. Serum levels of interleukin-6, as a reflect of disease severity in plasma cell dyscrasias. J. Clin Invest., 84: 2008-2011, 1989.
24. Berek, J. S., Chung, C , Khaldi, K. J., Watson, M., Knox, R. M., and Martinez-Maza, O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am. J. Obstct. Gynecol., 164: 1038-1042, 1991.
25. Armstrong, C., Tara, D. T., Hart, C. E., Kôck, A., Luger, T. A., and Ancel, J. C. Heterogeneity of cytokine production by human malignant melanoma cells Exp Dermatol., 1: 37-45, 1992.
26. Lee, J. D , Sievers, T. M., Skotzko, M., Chandler, C. F., Morton, D. L., McBride, W. H., and Economou, J. S. Interleukin-6 production by human melanoma cell lines. Lytnphokine Cytokine Res., 11: 161-166, 1992.
27. Tritareli, E , Rocca, E., Testa, U., Boccoli, G., Camagna, A., Calabresi, F., and Peschle, C. Adoptive immunotherapy with high dose interleukin-2: kinetics of circulating progenitors correlate with interleukin-6, granulocyte colony stimulating factor level. Blood, 74: 74-79, 1991.
28. List, J., Moser, R. P., Steuer, M , London, W. G., Blacklock, J. B., and Grimm, E. A. Cytokine response to intraventricular injection of interleukin-2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor α, interleukin 1β, interleukin 6, γ-interferon, and soluble interleukin 2 receptor. Cancer Res., 52: 1123-1128, 1992.
29. Haworth, C., Reilly, S. M., Chu, U., Rustin, G. J., and Feldmann, M. Flavone acetic acid with recombinant interleukin-2 in advanced malignant melanoma. III: Cytokine studies. Br. J. Cancer, 67: 1346-1350, 1993.
30. McIntyre, C. A., Chapman, K., Reeder, S., Dorreen, M. S., Bruce, L., Rodgers, S., Hayat, K., Schreenivasan, T, Sheridan, E., and Hancock, B. W. Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine level in sera and culture supernatants Eur. J. Cancer, 28: 58-63, 1992.
31. Lu, C , Vckers, M. F., and Kerbel, R. S. Interleukin-6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc. Natl. Acad. Sci. USA, 89: 9215-9219, 1992.
32. Lu, C., and Kerbel, R. S. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell Biol., 120: 1281-1288, 1993.
33. Armstrong, C., Murray, N., Kennedy, M., Koppula, S. V., Tara, D., and Ansel, J. C. Melanoma-derived interleukin-6 inhibits in vivo melanoma growth. J. Invest. Dermatol., 102: 278-284, 1994.
34. Shih, I-M., and Herlyn, M. Role of growth factors and their receptors in the development and progression of melanoma cells. J. Invest. Dermatol , 100: 196s-203s, 1993.
35. Sporn, M. B., and Roberts, A. B. Autocrine growth factors and cancer. Nature (Lond.), 303: 745-747, 1985.
36. Aaronson, S. A. Growth factors and cancer. Science (Washington DC), 254: 1146-1153, 1991.